Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Buy
69
AVXL Quote, Financials, Valuation and Earnings
Last price:
$11.48
Seasonality move
:
0.36%
Day range:
$10.87 - $11.18
52-week range:
$4.93 - $14.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.51x
Volume:
882.8K
Avg. volume:
945.6K
1-year change:
124.9%
Market cap:
$948.5M
Revenue:
--
EPS (TTM):
-$0.55
Analysts' Opinion
-
Consensus RatingAnavex Life Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $34.33, Anavex Life Sciences has an estimated upside of 209.03% from its current price of $11.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $11.11.
Fair Value
-
According to the consensus of 2 analysts, Anavex Life Sciences has 209.03% upside to fair value with a price target of $34.33 per share.
AVXL vs. S&P 500
-
Over the past 5 trading days, Anavex Life Sciences has overperformed the S&P 500 by 3.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Anavex Life Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Anavex Life Sciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Anavex Life Sciences reported revenues of --.
Earnings Growth
-
Anavex Life Sciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Anavex Life Sciences reported earnings per share of -$0.13.
Enterprise value:
832.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-27.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$56.5M | -$49.7M | -$55M | -$12.2M | -$12.4M | |
| EBITDA | -$53.8M | -$45M | -$50M | -$12.2M | -$12.4M | |
| Diluted EPS | -$0.68 | -$0.51 | -$0.55 | -$0.13 | -$0.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $83.6M | $160.3M | $159.2M | $144.5M | $117.1M | |
| Total Assets | $83.6M | $160.3M | $159.2M | $144.5M | $117.1M | |
| Current Liabilities | $7.8M | $8.1M | $14M | $9.6M | $17.4M | |
| Total Liabilities | $7.8M | $8.1M | $14M | $9.6M | $17.4M | |
| Total Equity | $75.8M | $152.2M | $145.2M | $135M | $99.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.4M | -$32.5M | -$29.8M | -$11.7M | -$5.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $25.5M | $18.4M | $6.2M | $7.3M | $852K | |
| Free Cash Flow | -$25.4M | -$32.5M | -$29.8M | -$11.7M | -$5.9M | |
AVXL
Sector
Market Cap
$948.5M
$34.5M
Price % of 52-Week High
76.94%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
124.9%
-35.15%
Beta (5-Year)
0.717
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.49
200-day SMA
Buy
Level
$8.53
Bollinger Bands (100)
Buy
Level
7.97 - 9.61
Chaikin Money Flow
Sell
Level
-268.3M
20-day SMA
Buy
Level
$9.62
Relative Strength Index (RSI14)
Buy
Level
69.76
ADX Line
Buy
Level
38.51
Williams %R
Sell
Level
-3.5398
50-day SMA
Buy
Level
$8.74
MACD (12, 26)
Buy
Level
0.66
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
278.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Stock Forecast FAQ
In the current month, AVXL has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AVXL average analyst price target in the past 3 months is $34.33.
-
Where Will Anavex Life Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Anavex Life Sciences share price will rise to $34.33 per share over the next 12 months.
-
What Do Analysts Say About Anavex Life Sciences?
Analysts are divided on their view about Anavex Life Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Anavex Life Sciences is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Anavex Life Sciences's Price Target?
The price target for Anavex Life Sciences over the next 1-year time period is forecast to be $34.33 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AVXL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Anavex Life Sciences is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVXL?
You can purchase shares of Anavex Life Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Anavex Life Sciences shares.
-
What Is The Anavex Life Sciences Share Price Today?
Anavex Life Sciences was last trading at $11.48 per share. This represents the most recent stock quote for Anavex Life Sciences. Yesterday, Anavex Life Sciences closed at $11.11 per share.
-
How To Buy Anavex Life Sciences Stock Online?
In order to purchase Anavex Life Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 1.02% over the past day.
